Personalis, Inc. (NASDAQ:PSNL) is listed among the 12 Best Genomics Stocks to Invest In. Morgan Stanley analyst Kallum Titchmarsh initiated coverage on PSNL with an Equal Weight rating and a price target of $11. Personalis revised its 2025 sales forecast, lowering it to a range of $68 million to $73 million while adjusting revenue projections for different client categories. The company provides genomic sequencing and analytics technologies for cancer immunotherapies. Despite the potential of PSNL as an investment, other AI stocks may offer greater upside. No promotional content included in the news article.

Read more at Yahoo Finance: Morgan Stanley Analyst Initiates Equal Weight Rating On Personalis, Inc. (PSNL)